Link Between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies

Overview

Journal South Asian J Cancer

Specialty Oncology

Date 2023 Nov 16

PMID 37969688

Authors

Krishna Prasad

Suresh Rao

Sanath Kumar Hegde

Thomas George

Rhea Katherine Dsouza

Sucharitha Suresh

Manjeshwar Shrinath Baliga

Affiliations

Soon will be listed here.

Abstract

Krishna Prasad Development of treatment-induced hyperglycemia/diabetes is a considerable problem in women undergoing chemotherapy for breast cancer. In this study, baseline levels of blood cell-associated inflammatory indices (BCAII) were analyzed to understand their role in the development of treatment-induced hyperglycemia and diabetogenesis. This was a retrospective study, and information on women who were normoglycemic and nondiabetic and of women who were diabetic at the beginning of the treatment were collected from files. Demographic, pathology-related details, and complete blood profile were noted. Neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII) which indicate BCAII were calculated. Demographic details were subjected to frequency and percentage, while blood parameters were subjected to one-way analysis of variance followed by post hoc Bonferroni's multiple comparison tests. A -value of <0.05 was considered significant. The results indicated that a significant difference in levels of total count ( < 0.035), neutrophil, lymphocyte, and platelets ( < 0.001) were observed. Regarding BCAII, when compared with women who were normoglycemic at the end of treatment, NLR, dNLR, PLR, and SII were significantly high for people who were known diabetics at the beginning of treatment ( < 0.001). The dNLR ( = 0.0008), PLR ( < 0.001), and SII ( < 0.001) were significant for people who developed secondary hyperglycemia/diabetes, while only dNLR was significant for people who progressed from normal to prediabetes stage ( = 0.049) To the best of the authors' knowledge, this is the first study that indicates difference in baseline BCAII and development of treatment-induced hyperglycemia/diabetes indicating that underlying low levels of inflammation may contribute to diabetogenesis in women affected with breast cancer.

References

Khokhar A . Breast cancer in India: where do we stand and where do we go?. Asian Pac J Cancer Prev. 2012; 13(10):4861-6. DOI: 10.7314/apjcp.2012.13.10.4861. View

Demirdal T, Sen P . The significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and lymphocyte-monocyte ratio in predicting peripheral arterial disease, peripheral neuropathy, osteomyelitis and amputation in diabetic foot infection. Diabetes Res Clin Pract. 2018; 144:118-125. DOI: 10.1016/j.diabres.2018.08.009. View

Hwangbo Y, Lee E . Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinol Metab (Seoul). 2017; 32(1):23-29. PMC: 5368117. DOI: 10.3803/EnM.2017.32.1.23. View

Gallagher E, Fei K, Feldman S, Port E, Friedman N, Boolbol S . Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. Breast Cancer Res. 2020; 22(1):40. PMC: 7216707. DOI: 10.1186/s13058-020-01281-y. View

Janelsins M, Tejani M, Kamen C, Peoples A, Mustian K, Morrow G . Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013; 14(6):757-66. PMC: 3938333. DOI: 10.1517/14656566.2013.776541. View

Lipscombe L, Chan W, Yun L, Austin P, Anderson G, Rochon P . Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia. 2012; 56(3):476-83. DOI: 10.1007/s00125-012-2793-9. View

Agnoli C, Berrino F, Abagnato C, Muti P, Panico S, Crosignani P . Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis. 2009; 20(1):41-8. PMC: 2819536. DOI: 10.1016/j.numecd.2009.02.006. View

Dieli-Conwright C, Wong L, Waliany S, Bernstein L, Salehian B, Mortimer J . An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer. 2016; 122(17):2646-53. PMC: 4992442. DOI: 10.1002/cncr.30104. View

Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C . Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015; 38(12):1153-68. DOI: 10.1007/s40264-015-0339-z. View

10.

Kokiwar P, Kumar H, Mubashare A . Epidemiological and clinical profile of breast cancer patients at a tertiary care hospital in South India. J Cancer Res Ther. 2011; 7(1):95. DOI: 10.4103/0973-1482.80445. View

11.

Juanjuan L, Wen W, Zhongfen L, Chuang C, Jing C, Yiping G . Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study. Tumour Biol. 2015; 36(9):6939-47. PMC: 4644204. DOI: 10.1007/s13277-015-3380-8. View

12.

Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A . Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014; 15(8):3353-8. DOI: 10.7314/apjcp.2014.15.8.3353. View

13.

Mertoglu C, Gunay M . Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2016; 11 Suppl 1:S127-S131. DOI: 10.1016/j.dsx.2016.12.021. View

14.

Hickish T, Astras G, Thomas P, Penfold S, Purandare L, Hickish T . Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2009; 101(7):537. DOI: 10.1093/jnci/djp025. View

15.

Vidler J, Rogers C, Yallop D, Devereux S, Wellving E, Stewart O . Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. J Clin Transl Endocrinol. 2017; 9:18-20. PMC: 5651285. DOI: 10.1016/j.jcte.2017.06.003. View

16.

Wu Y, Liu Y, Dong Y, Vadgama J . Diabetes-associated dysregulated cytokines and cancer. Integr Cancer Sci Ther. 2018; 3(1):370-378. PMC: 6007890. DOI: 10.15761/ICST.1000173. View

17.

Sharma G, Dave R, Sanadya J, Sharma P, Sharma K . Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2012; 1(2):109-26. PMC: 3255438. View

18.

Tsalamandris S, Antonopoulos A, Oikonomou E, Papamikroulis G, Vogiatzi G, Papaioannou S . The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019; 14(1):50-59. PMC: 6523054. DOI: 10.15420/ecr.2018.33.1. View

19.

Jeong Y, Han H, Lee H, Yang J, Jeong J, Choi M . A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients. Cancer Res Treat. 2016; 48(4):1429-1437. PMC: 5080830. DOI: 10.4143/crt.2015.464. View

20.

Li X, Teng L, Yang Z . Editorial: From Chronic Inflammation to Cancer: How Far Can Immunotherapy Go?. Front Pharmacol. 2022; 12:838917. PMC: 8820386. DOI: 10.3389/fphar.2021.838917. View